Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A; LYCY Study Group. Dell'Agnello G, et al. Among authors: escobar r. Eur Neuropsychopharmacol. 2009 Nov;19(11):822-34. doi: 10.1016/j.euroneuro.2009.07.008. Epub 2009 Aug 28. Eur Neuropsychopharmacol. 2009. PMID: 19716683 Clinical Trial.
Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, García-Polavieja MJ, Gilaberte I, Escobar R. Montoya A, et al. Among authors: escobar r. Curr Med Res Opin. 2009 Nov;25(11):2745-54. doi: 10.1185/03007990903316152. Curr Med Res Opin. 2009. PMID: 19785510 Clinical Trial.
Prognostic factors of improvement in health-related quality of life in atomoxetine-treated children and adolescents with attention-deficit/hyperactivity disorder, based on a pooled analysis.
Montoya A, Quail D, Anand E, Cardo E, Alda JA, Escobar R. Montoya A, et al. Among authors: escobar r. Atten Defic Hyperact Disord. 2014 Mar;6(1):25-34. doi: 10.1007/s12402-013-0119-5. Epub 2013 Oct 20. Atten Defic Hyperact Disord. 2014. PMID: 24142305 Free PMC article.
Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine.
Montoya A, Escobar R, García-Polavieja MJ, Lachno DR, Alda JÁ, Artigas J, Cardo E, García M, Gastaminza X, Gilaberte I. Montoya A, et al. Among authors: escobar r. J Child Neurol. 2011 Jan;26(1):31-6. doi: 10.1177/0883073810371981. Epub 2010 Jun 4. J Child Neurol. 2011. PMID: 20525942 Clinical Trial.
Predictors of relapse or maintenance of response in pediatric and adult patients with attention-deficit/hyperactivity disorder following discontinuation of long-term treatment with atomoxetine.
Thome J, Dittmann RW, Greenhill LL, Lipsius S, Tanaka Y, Bushe C, Escobar R, Heinloth AN, Upadhyaya H. Thome J, et al. Among authors: escobar r. Atten Defic Hyperact Disord. 2017 Dec;9(4):219-229. doi: 10.1007/s12402-017-0227-8. Epub 2017 May 5. Atten Defic Hyperact Disord. 2017. PMID: 28477289
176 results